Resolution n° 6-2017-e

Costed extension of Unitaid project support to WHO Prequalification of Medicines and Diagnostics

Recalling Unitaid Board Resolution EB19/2013/R5 of 12-13 December 2013 in which the Board approved the commitment of up to US$ 50,303,408 for the project entitled “Increased access to appropriate, quality assured diagnostics, medical devices and medicines for prevention, initiation and treatment of HIV/AIDS, TB and malaria” (the “Project”) to be implemented by WHO Prequalification Programme (“WHO/PQ”) for a three-year period and noting that, in 2016, the Unitaid Secretariat approved a six-month no cost extension to funding for the Project ending on 30 June 2017,

Acknowledging the need for Unitaid to assess how any future funding would fit within its current Strategy; and

Noting the need for both WHO/PQ and Unitaid to work with other stakeholders and potential funders, with a view to aligning on the future global need and scope for prequalification, as well as with respect to investment approaches;

The Board authorizes, subject to the availability of funds, the Executive Director to commit an additional amount of up to US$ 21,444,475 for the Project, subject to the signature of the legal agreement between WHO/RHT and Unitaid.

**Lead Organisation:** World Health Organization Regulation of Medicines and other Health Technologies (RHT) / Prequalification (PQ)

**Project Duration:** 18 months to 31 December 2018

\[\text{Signature of Celso Amorim}\]

Celso Amorim  
Chair of the UNITAID Executive Board

**Date:** 28/06/2017